Literature DB >> 15247187

Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.

K Tominaga1, S Kuriyama, H Yoshiji, A Deguchi, Y Kita, F Funakoshi, T Masaki, K Kurokohchi, N Uchida, T Tsujimoto, H Fukui.   

Abstract

BACKGROUND: Systemic adenoviral readministration appears to be limited by immunogenicity. AIMS: We examined the feasibility of repeated adenovirus mediated gene transfer into the liver via the biliary tract.
METHODS: Recombinant adenoviruses carrying a reporter lacZ gene were infused retrogradely into the common bile duct of rats. Transduction efficiency of the lacZ gene was estimated histochemically and quantitatively.
RESULTS: Retrograde administration of recombinant adenoviruses into the common bile duct of rats resulted in efficient transgene expression in the liver, specifically in hepatocytes, but not in biliary epithelia. Transduction efficiency induced by intrabiliary adenoviral administration was not substantially different from that induced by intraportal adenoviral infusion. Transgene expression in the liver was however transient, and development of neutralising antibodies against adenovirus was observed in serum but not in bile. When adenoviruses were readministered into the common bile duct, successful re-expression of the transgene in the liver was achieved despite the existence of neutralising antibodies in serum. Interestingly, although proliferation of adenovirus specific T cells in response to adenoviral readministration was suppressed significantly by immunosuppressive FK506 treatment, levels of transgene expression in the liver achieved by intrabiliary adenoviral readministration were not significantly different between animals treated with and without FK506. Furthermore, third adenoviral administration into the common bile duct also induced successful transgene expression in the liver.
CONCLUSIONS: These results suggest that adenovirus mediated gene transfer into the liver may be repeatable without immunosuppressive strategies in clinical settings by means of endoscopic retrograde cholangiography.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247187      PMCID: PMC1774146          DOI: 10.1136/gut.2003.013748

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Intravenous readministration of an adenoviral vector performed long after the initial administration failed to induce re-expression of the original transgene in rats.

Authors:  H Tsujinoue; S Kuriyama; K Tominaga; H Okuda; T Nakatani; H Yoshiji; T Tsujimoto; T Akahane; K Asada; H Fukui
Journal:  Int J Oncol       Date:  2001-03       Impact factor: 5.650

2.  Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver.

Authors:  S Kuriyama; K Tominaga; A Mitoro; H Tsujinoue; T Nakatani; M Yamazaki; S Nagao; Y Toyokawa; S Okamoto; H Fukui
Journal:  Int J Cancer       Date:  2000-03-15       Impact factor: 7.396

3.  Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver.

Authors:  S Kuriyama; K Tominaga; M Kikukawa; T Tsujimoto; T Nakatani; H Tsujinoue; H Okuda; S Nagao; A Mitoro; H Yoshiji; H Fukui
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

4.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers.

Authors:  T Nakatani; S Kuriyama; K Tominaga; T Tsujimoto; A Mitoro; M Yamazaki; H Tsujinoue; H Yoshiji; S Nagao; H Fukui
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses.

Authors:  K F Kozarsky; D R McKinley; L L Austin; S E Raper; L D Stratford-Perricaudet; J M Wilson
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

7.  Neutralizing antibodies against 33 human adenoviruses in normal children in Rome.

Authors:  E D'Ambrosio; N Del Grosso; A Chicca; M Midulla
Journal:  J Hyg (Lond)       Date:  1982-08

8.  Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population.

Authors:  A Weinberg; M C Fink; S Takimoto; M A Ishida; M C Souza
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1989 Sep-Oct       Impact factor: 1.846

9.  A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector.

Authors:  S Kuriyama; M Yoshikawa; S Ishizaka; T Tsujii; K Ikenaka; T Kagawa; N Morita; K Mikoshiba
Journal:  Cell Struct Funct       Date:  1991-12       Impact factor: 2.212

10.  Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.

Authors:  Y Nakamura; H Wakimoto; J Abe; Y Kanegae; I Saito; M Aoyagi; K Hirakawa; H Hamada
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

View more
  7 in total

Review 1.  Gene therapy for liver regeneration: experimental studies and prospects for clinical trials.

Authors:  Hussein-M Atta
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

2.  Transient depletion of kupffer cells leads to enhanced transgene expression in rat liver following retrograde intrabiliary infusion of plasmid DNA and DNA nanoparticles.

Authors:  Hui Dai; Xuan Jiang; Kam W Leong; Hai-Quan Mao
Journal:  Hum Gene Ther       Date:  2011-03-04       Impact factor: 5.695

Review 3.  Cholangiocyte anion exchange and biliary bicarbonate excretion.

Authors:  Jesús-M Banales; Jesus Prieto; Juan-F Medina
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

4.  Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis.

Authors:  Kohji Kinoshita; Yuji Iimuro; Jiro Fujimoto; Yutaka Inagaki; Kazuhiko Namikawa; Hiroshi Kiyama; Yuji Nakajima; Kohji Otogawa; Norifumi Kawada; Scott L Friedman; Kazuo Ikeda
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

5.  Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats.

Authors:  Kohji Kinoshita; Yuji Iimuro; Kohji Otogawa; Shizuya Saika; Yutaka Inagaki; Yuji Nakajima; Norifumi Kawada; Jiro Fujimoto; Scott L Friedman; Kazuo Ikeda
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

6.  Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery.

Authors:  Hui Dai; Xuan Jiang; Geoffrey C Y Tan; Yong Chen; Michael Torbenson; Kam W Leong; Hai-Quan Mao
Journal:  Int J Nanomedicine       Date:  2006

7.  Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts.

Authors:  Anabel José; Luciano Sobrevals; Juan Miguel Camacho-Sánchez; Meritxell Huch; Núria Andreu; Eduard Ayuso; Pilar Navarro; Ramon Alemany; Cristina Fillat
Journal:  Oncotarget       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.